Compare Stocks: RLYB, SABS, NLTX, and IRD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IRD Opus Genetics	$3.61 -3.0%	$3.76	$1.10 ▼ $5.81	$298.36M	0.59	847,977 shs	414,229 shs
NLTX Neoleukin Therapeutics	$36.14 +1.4%	$33.89	$2.03 ▼ $14.36	$339.64M	1.11	50,104 shs	115,860 shs
RLYB Rallybio	$16.99 +0.2%	$16.09	$3.67 ▼ $17.57	$90.23M	-0.9	29,170 shs	12,921 shs
SABS SAB Biotherapeutics	$3.70 -1.3%	$3.72	$1.85 ▼ $5.15	$336.65M	0.53	485,132 shs	324,201 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IRD Opus Genetics	0.00%	-1.37%	+10.06%	-24.79%	+228.18%
NLTX Neoleukin Therapeutics	+1.43%	+1.26%	-8.39%	+21.19%	+88.03%
RLYB Rallybio	0.00%	+5.14%	+6.45%	+18.81%	+296.67%
SABS SAB Biotherapeutics	0.00%	-5.13%	+1.09%	0.00%	+72.09%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IRD Opus Genetics	$3.61 -3.0%	$3.76	$1.10 ▼ $5.81	$298.36M	0.59	847,977 shs	414,229 shs
NLTX Neoleukin Therapeutics	$36.14 +1.4%	$33.89	$2.03 ▼ $14.36	$339.64M	1.11	50,104 shs	115,860 shs
RLYB Rallybio	$16.99 +0.2%	$16.09	$3.67 ▼ $17.57	$90.23M	-0.9	29,170 shs	12,921 shs
SABS SAB Biotherapeutics	$3.70 -1.3%	$3.72	$1.85 ▼ $5.15	$336.65M	0.53	485,132 shs	324,201 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IRD Opus Genetics	0.00%	-1.37%	+10.06%	-24.79%	+228.18%
NLTX Neoleukin Therapeutics	+1.43%	+1.26%	-8.39%	+21.19%	+88.03%
RLYB Rallybio	0.00%	+5.14%	+6.45%	+18.81%	+296.67%
SABS SAB Biotherapeutics	0.00%	-5.13%	+1.09%	0.00%	+72.09%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IRD Opus Genetics	2.89	Moderate Buy	$10.69	196.19% Upside
NLTX Neoleukin Therapeutics	0.00	N/A	N/A	N/A
RLYB Rallybio	1.00	Sell	N/A	N/A
SABS SAB Biotherapeutics	2.73	Moderate Buy	$12.00	224.32% Upside

Current Analyst Ratings Breakdown

Latest RLYB, SABS, NLTX, and IRD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2026	IRD Opus Genetics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/7/2026	IRD Opus Genetics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$10.00 ➝ $9.00
8/6/2026	SABS SAB Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (E+)
8/5/2026	RLYB Rallybio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/29/2026	IRD Opus Genetics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
7/17/2026	IRD Opus Genetics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/13/2026	IRD Opus Genetics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/8/2026	SABS SAB Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D+)
7/6/2026	IRD Opus Genetics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$13.00
7/6/2026	IRD Opus Genetics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$12.00
6/24/2026	SABS SAB Biotherapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$13.00

(Data available from 8/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IRD Opus Genetics	$14.20M	21.01	N/A	N/A	($0.16) per share	-22.56
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	$11.08 per share	N/A
RLYB Rallybio	$646K	139.68	N/A	N/A	$17.79 per share	0.96
SABS SAB Biotherapeutics	$1.32M	255.05	$0.34 per share	10.83	$2.36 per share	1.57

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IRD Opus Genetics	-$49.59M	-$1.35	N/A	N/A	N/A	-1,091.82%	-338.88%	-150.13%	N/A
NLTX Neoleukin Therapeutics	-$57.56M	-$3.11	N/A	N/A	N/A	N/A	-37.22%	-30.91%	N/A
RLYB Rallybio	-$8.98M	-$4.34	N/A	N/A	N/A	-911.07%	-40.53%	-38.13%	N/A
SABS SAB Biotherapeutics	$13.27M	-$1.30	N/A	N/A	N/A	N/A	-6.74%	-6.06%	N/A

Latest RLYB, SABS, NLTX, and IRD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	IRD Opus Genetics	-$0.1567	-$0.14	+$0.0167	-$0.14	$2.63 million	$0.76 million
8/6/2026	Q2 2026	RLYB Rallybio	-$1.28	-$1.09	+$0.19	$7.53	N/A	N/A
8/6/2026	Q2 2026	SABS SAB Biotherapeutics	-$0.2830	-$0.28	+$0.0030	-$0.28	$0.13 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IRD Opus Genetics	N/A	N/A	N/A	N/A	N/A
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	N/A
RLYB Rallybio	N/A	N/A	N/A	N/A	N/A
SABS SAB Biotherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IRD Opus Genetics	N/A	12.19	12.19
NLTX Neoleukin Therapeutics	N/A	15.33	15.33
RLYB Rallybio	N/A	27.26	27.26
SABS SAB Biotherapeutics	0.01	9.22	9.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IRD Opus Genetics	14.97%
NLTX Neoleukin Therapeutics	52.37%
RLYB Rallybio	90.34%
SABS SAB Biotherapeutics	7.82%

Insider Ownership

Company	Insider Ownership
IRD Opus Genetics	11.70%
NLTX Neoleukin Therapeutics	1.58%
RLYB Rallybio	10.30%
SABS SAB Biotherapeutics	7.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IRD Opus Genetics	14	82.65 million	72.98 million	N/A
NLTX Neoleukin Therapeutics	90	9.40 million	9.25 million	No Data
RLYB Rallybio	40	5.31 million	4.76 million	Not Optionable
SABS SAB Biotherapeutics	140	90.99 million	84.26 million	Not Optionable

RLYB, SABS, NLTX, and IRD Headlines

Recent News About These Companies

SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Consensus Rating of "Moderate Buy" from Brokerages

August 11, 2026 | marketbeat.com

HC Wainwright Issues Pessimistic Outlook for SABS Earnings

August 10, 2026 | americanbankingnews.com

Q3 EPS Estimate for SAB Biotherapeutics Boosted by Analyst

August 10, 2026 | marketbeat.com

What is HC Wainwright's Estimate for SABS Q3 Earnings?

August 10, 2026 | marketbeat.com

SAB Biotherapeutics (NASDAQ:SABS) Raised to "Sell" at Wall Street Zen

August 10, 2026 | americanbankingnews.com

SAB Biotherapeutics (NASDAQ:SABS) Upgraded by Wall Street Zen to "Sell" Rating

August 10, 2026 | marketbeat.com

SABS FY2030 EPS Estimate Lifted by Brookline Capital Markets

August 9, 2026 | americanbankingnews.com

Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI) and SAB Biotherapeutics (SABS)

August 8, 2026 | theglobeandmail.com

SAB Biotherapeutics Q2 Earnings Call Highlights

August 7, 2026 | marketbeat.com

SABS FY2030 EPS Boosted by Brookline Capital Markets

August 7, 2026 | marketbeat.com

SAB Biotherapeutics (NASDAQ:SABS) Posts Earnings Results, Hits Estimates

August 6, 2026 | marketbeat.com

SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights

August 6, 2026 | globenewswire.com

Seven Fleet Capital Management LP Takes Position in SAB Biotherapeutics, Inc. $SABS

August 2, 2026 | marketbeat.com

Perceptive Advisors LLC Buys 5,628,533 Shares of SAB Biotherapeutics, Inc. $SABS

August 2, 2026 | marketbeat.com

DV Trading LLC Takes $1.53 Million Position in SAB Biotherapeutics, Inc. $SABS

August 2, 2026 | marketbeat.com

SAB Biotherapeutics (NASDAQ:SABS) Downgraded by Wall Street Zen to Strong Sell

August 2, 2026 | marketbeat.com

SAB Biotherapeutics (SABS) Projected to Release Quarterly Earnings on Thursday

July 30, 2026 | marketbeat.com

Affinity Asset Advisors LLC Invests $2.20 Million in SAB Biotherapeutics, Inc. $SABS

July 25, 2026 | marketbeat.com

SAB Biotherapeutics (NASDAQ:SABS) Upgraded to "Sell" at Wall Street Zen

July 25, 2026 | marketbeat.com

Monashee Investment Management LLC Invests $1.92 Million in SAB Biotherapeutics, Inc. $SABS

July 23, 2026 | marketbeat.com

SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

July 17, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLYB, SABS, NLTX, and IRD Company Descriptions

Opus Genetics NASDAQ:IRD

$3.61 -0.11 (-2.96%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$3.67 +0.06 (+1.66%)

As of 08/14/2026 07:34 PM Eastern

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.

Neoleukin Therapeutics NASDAQ:NLTX

$36.14 +0.51 (+1.43%)

As of 08/14/2026

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

Rallybio NASDAQ:RLYB

$16.99 +0.03 (+0.18%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$16.98 0.00 (-0.03%)

As of 08/14/2026 07:41 PM Eastern

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.

SAB Biotherapeutics NASDAQ:SABS

$3.70 -0.05 (-1.33%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$3.64 -0.06 (-1.49%)

As of 08/14/2026 07:34 PM Eastern

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RLYB, SABS, NLTX, and IRD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RLYB, SABS, NLTX, and IRD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RLYB, SABS, NLTX, and IRD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLYB, SABS, NLTX, and IRD Company Descriptions

Opus Genetics NASDAQ:IRD

Neoleukin Therapeutics NASDAQ:NLTX

Rallybio NASDAQ:RLYB

SAB Biotherapeutics NASDAQ:SABS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RLYB, SABS, NLTX, and IRD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RLYB, SABS, NLTX, and IRD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RLYB, SABS, NLTX, and IRD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLYB, SABS, NLTX, and IRD Company Descriptions

Opus Genetics NASDAQ:IRD

Neoleukin Therapeutics NASDAQ:NLTX

Rallybio NASDAQ:RLYB

SAB Biotherapeutics NASDAQ:SABS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools